Dienogest versus Leuprolide prior to in-vitro-fertilization (IVF) cycle in women with endometriosis associated infertility

Phase 4

Active, not recruiting

• Registration Number: CTRI/2019/07/020185
• Lead Sponsor: Institute

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2021-11-24

Recruitment & Eligibility

• Status: Closed to Recruitment of Participants
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1)Endometriosis planned for IVF

2)Diagnosed endometriosis at laparoscopy and or USG

3)FSH <= 12 IU/L, AMH >= 1.5 ng/ml

4)Willing to participate in the study

Exclusion Criteria

1)Recurrent endometrioma

2)Prior surgery on ovary including endometrioma drainage /cystectomy

3)BMI > 30 kg/m2

4)Uterine factor unfavorable for implantation (adenomyosis, intrauterine adhesions, thin endometrium, submucous fibroids)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Clinical pregnancy rate <br/ ><br>Timepoint: 4 months from date of 1st recruitment

Secondary Outcome Measures

Name	Time	Method
1)Response to COS <br/ ><br>a)Total dose of gonadotropins <br/ ><br>b)Number of days of stimulation <br/ ><br>c)Total number of oocytes retrieved <br/ ><br>d)Number of metaphase II oocytes <br/ ><br>e)Total number of embryos <br/ ><br>f)Fertilization rate <br/ ><br>g)Cleavage rate <br/ ><br>h)Number of grade 1 embryos <br/ ><br>i)OHSS rate <br/ ><br>2)Implantation rate <br/ ><br>3)Miscarriage rate <br/ ><br>4)Ectopic pregnancy rate <br/ ><br>5)Live Birth Rate <br/ ><br>Timepoint: 2 yrs 6 months from date of first recruitment